Discover
IVVD
Invivyd, Inc.
0.85
2 x 0.62
2 x 1.09
bid
ask
-
0.02
2.06%
2 @ 04:00 PM
0.85 -0.00 (0.51%)
| Ytd | -65.41% | |
| 1y | 18.50% |
0.83
day range
0.90
0.48
52 week range
3.07
| Open | 0.89 | Prev Close | 0.87 | Low | 0.83 | High | 0.90 | Mkt Cap | 251.71M |
| Vol | 2.89M | Avg Vol | 4.40M | EPS | -0.29 | P/E | N/A | Forward P/E | -2.36 |
| Beta | 0.66 | Short Ratio | 23.71 | Inst. Own | 79.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.17 | 200-d Avg | 1.69 | 1yr Est | 5.89 |
IVVD News
globenewswire.com
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
benzinga.com
Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An m
Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparis
benzinga.com
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy a
benzinga.com
Invivyd Dosed The First Participants In LIBERTY Phase 3 Trial Of VYD2311 Alone, And VYD2311 Co-admin
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA
benzinga.com
Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and e